Filing Details
- Accession Number:
- 0001645113-22-000017
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-03-07 18:18:57
- Reporting Period:
- 2022-03-03
- Accepted Time:
- 2022-03-07 18:18:57
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1645113 | Novocure Ltd | NVCR | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1632237 | Ely Benaim | C/O Novocure Inc., 20 Valley Stream Parkway, Suite 300 Malvern PA 19355 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2022-03-03 | 17,371 | $0.00 | 45,570 | No | 4 | A | Direct | |
| Ordinary Shares | Disposition | 2022-03-03 | 803 | $74.50 | 44,767 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2022-03-04 | 1,510 | $70.41 | 43,257 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Options to Buy Ordinary Shares | Acquisiton | 2022-03-03 | 30,422 | $80.59 | 30,422 | $80.59 |
| Ordinary Shares | Options to Buy Ordinary Shares | Acquisiton | 2022-03-03 | 5,452 | $80.59 | 5,452 | $80.59 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 30,422 | 2023-03-01 | 2032-02-29 | No | 4 | A | Direct |
| 5,452 | 2023-03-01 | 2032-02-29 | No | 4 | A | Direct |
Footnotes
- Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
- Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
- Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.
Billionaire Hedge Funds
